Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protara Therapeutics Q3 EPS $(0.87) Beats $(0.98) Estimate; Cash, Cash Equivalents And Investments Of $74M As Of September 30, 2023 Expected To Fund Operations Into Q2 Of 2025

Author: Benzinga Newsdesk | November 03, 2023 08:14am
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(0.98) by 11.22 percent. This is a 27.94 percent decrease over losses of $(0.68) per share from the same period last year.

Posted In: TARA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist